Zhejiang Medicine Co Ltd (600216) — Capital Reinvestment Ratio
Zhejiang Medicine Co Ltd (600216) has a Capital Reinvestment Ratio of 0.12x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥690.77 Million) in capital expenditures (CN¥80.03 Million). Check 600216 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Medicine Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Zhejiang Medicine Co Ltd's Capital Reinvestment Ratio across 27 annual periods. For the full cash flow conversion analysis, see Zhejiang Medicine Co Ltd operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Zhejiang Medicine Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Medicine Co Ltd from 1998 to 2025. See Zhejiang Medicine Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | CN¥1.89 Billion | CN¥446.47 Million | ▼ -58.0% |
| 2024 | 0.56x | CN¥1.22 Billion | CN¥689.14 Million | ▼ -55.2% |
| 2023 | 1.26x | CN¥634.31 Million | CN¥796.87 Million | ▼ -33.0% |
| 2022 | 1.87x | CN¥520.60 Million | CN¥975.99 Million | ▲ +126.8% |
| 2021 | 0.83x | CN¥1.14 Billion | CN¥939.60 Million | ▲ +94.1% |
| 2020 | 0.43x | CN¥1.26 Billion | CN¥535.35 Million | ▼ -66.8% |
| 2019 | 1.28x | CN¥447.25 Million | CN¥573.63 Million | ▲ +69.3% |
| 2018 | 0.76x | CN¥579.91 Million | CN¥439.30 Million | ▼ -33.1% |
| 2017 | 1.13x | CN¥503.47 Million | CN¥569.99 Million | ▼ -0.3% |
| 2016 | 1.14x | CN¥336.14 Million | CN¥381.76 Million | ▼ -83.3% |
| 2015 | 6.80x | CN¥106.54 Million | CN¥724.96 Million | ▲ +277.3% |
| 2014 | 1.80x | CN¥549.90 Million | CN¥991.76 Million | ▼ -0.5% |
| 2013 | 1.81x | CN¥655.09 Million | CN¥1.19 Billion | ▲ +54.8% |
| 2012 | 1.17x | CN¥807.49 Million | CN¥945.50 Million | ▲ +210.2% |
| 2011 | 0.38x | CN¥912.75 Million | CN¥344.58 Million | ▲ +240.6% |
| 2010 | 0.11x | CN¥1.32 Billion | CN¥145.90 Million | ▲ +6.0% |
| 2009 | 0.10x | CN¥1.47 Billion | CN¥153.13 Million | ▼ -3.7% |
| 2008 | 0.11x | CN¥1.20 Billion | CN¥130.27 Million | ▼ -83.9% |
| 2007 | 0.67x | CN¥227.67 Million | CN¥153.37 Million | ▼ -54.3% |
| 2006 | 1.47x | CN¥169.51 Million | CN¥249.99 Million | ▼ -89.2% |
| 2005 | 13.60x | CN¥25.14 Million | CN¥341.93 Million | ▲ +910.5% |
| 2004 | 1.35x | CN¥107.60 Million | CN¥144.80 Million | ▼ -32.2% |
| 2003 | 1.98x | CN¥66.20 Million | CN¥131.37 Million | ▼ -78.5% |
| 2002 | 9.25x | CN¥23.13 Million | CN¥213.81 Million | ▲ +654.2% |
| 2001 | 1.23x | CN¥98.25 Million | CN¥120.44 Million | ▼ -89.5% |
| 2000 | 11.69x | CN¥10.58 Million | CN¥123.69 Million | ▲ +435.0% |
| 1998 | 2.18x | CN¥57.72 Million | CN¥126.08 Million | — |